Dr. Reddy’s Laboratories launched Sugammadex Injection Single-Dose Vials, a generic equivalent of Bridion, in the United States (US). Sugammadex Injection is a vertically integrated product manufactured through Dr. Reddy’s global supply network. Dr. Reddy’s launch of the product is on the first day of generic availability in the United States, a release said.Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery.The Bridion brand (100mg/ml) had U.S. sales of approximately $1.6 billion for the latest 12-month period endedMay 2026, according to IQVIA National Sales Perspectives data.Bridion is a registered trademark of Merck Sharp & Dohme B.V.Published on August 4, 2026
Dr Reddy’s Laboratories launches Sugammadex injection in US
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients









